ARK Invest Divests ATAIBECKLEY Shares Amid Eli Lilly Acquisition, Increases Stake in X-Energy
ARK Invest sold approximately 1.12 million shares of ATAIBECKLEY valued at $6.02 million following Eli Lilly's confirmed acquisition. Concurrently, ARK raised its position in X-Energy by acquiring 507,347 shares worth $7.64 million, reflecting a strategic shift towards nuclear energy investments.
Theia Market Signal Identification - AI Assisted
On March 30, 2026, ARK Invest divested 1,123,010 shares of ATAIBECKLEY for $6,019,333 after Eli Lilly's acquisition announcement. Eli Lilly is offering $6.75 per share plus a conditional payment of up to $2.50, equating to a 40% premium based on the 30-day volume-weighted average price.
The deal is set to finalize in Q3 2026. Simultaneously, ARK increased its investment in X-Energy, acquiring 507,347 shares through ARK Innovation ETF and ARK Autonomous Technology & Robotics ETF. X-Energy, which went public at $23 in April 2026, is developing small modular reactors and has over 140 planned in the U.S. and UK. Analysts project a significant upside for X-Energy, with an average target price of $38.71, indicating potential growth amidst rising demand for electricity from AI data centers.
Comments